Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | F3 | P13726 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598762 | 1.00 | JUN (1.00) | JUNNFKB1CYP1A2MAPTF3 | |
| Hydrochloric Acid SCHEMBL11970816 | 0.98 | JUN (0.95) | JUNNFKB1CYP1A2MAPTF3 | |
| Hydrochloric Acid SCHEMBL11970821 | 0.98 | JUN (0.95) | JUNNFKB1CYP1A2MAPTF3 | |
| SCHEMBL11999793 | 0.92 | JUN (0.84) | JUNNFKB1CYP1A2MAPTF3 | |
| Hydrochloric Acid SCHEMBL1490919 | 0.90 | JUN (0.81) | JUNNFKB1CYP1A2MAPTF3 | |
| SCHEMBL28574308 | 0.90 | NFKB1 (0.81) | JUNNFKB1CYP1A2MAPTF3 | |
| Hydrochloric Acid SCHEMBL1490918 | 0.90 | JUN (0.81) | JUNNFKB1CYP1A2MAPTF3 | |
| SCHEMBL7181746 | 0.87 | JUN (0.77) | JUNNFKB1CYP1A2MAPTF3 | |
| SCHEMBL7181745 | 0.87 | JUN (0.77) | JUNNFKB1CYP1A2MAPTF3 | |
| SCHEMBL333511 | 0.84 | NFKB1 (0.72) | JUNNFKB1CYP1A2MAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2019-08-01 | — | — | US | disclosed |
| EP-3188721-B1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LTD (IE) | 2019-06-12 | — | — | EP | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
| EP-1420009-A2 | Novel amino acid derivatives with improved multi-drug resistance activity | Vertex Pharmaceuticals Incorporated (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-0797567-B1 | NOVEL AMINO ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY | VERTEX PHARMA (US) | 2004-02-11 | — | — | EP | disclosed |
| US-6284778-B1 | NEUROTROPHIC AGENT | VERTEX PHARMACEUTICALS INCORPORATED | 2001-09-04 | — | — | US | disclosed |
| US-6172086-B1 | TREATING PARKINSON*S DISEASE, ALZHIEMER*S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS AND OTHER NERVOUS SYSTEM DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED | 2001-01-09 | — | — | US | disclosed |
| US-5840736-A | PEPTIDES FOR NERVE GROWTH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-11-24 | — | — | US | disclosed |
| US-5543423-A | USED IN MULTI-DRUG RESISTANCE CANCER THERAPY | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1996-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | JUN 2377/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | JUN 2579/4885NFKB1 1602/4885CYP1A2 1507/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | JUN 2204/4885NFKB1 418/4885CYP1A2 2544/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | JUN 2377/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | JUN 2377/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | JUN 2579/4885NFKB1 1602/4885CYP1A2 1507/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | JUN 2377/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | JUN 2377/4885NFKB1 841/4885CYP1A2 2166/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | JUN 2579/4885NFKB1 1602/4885CYP1A2 1507/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | JUN 786/4885NFKB1 73/4885CYP1A2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.